In political systems based on the principle of separation of powers, authority is distributed among several branches (executive, legislative, judicial) — an attempt to prevent the concentration of power in the hands of a small group of people. In such a system, the executive does not pass laws (the role of the legislature) or interpret them (the role of the judiciary). Instead, the executive enforces the law as written by the legislature and interpreted by the judiciary. The executive can be the source of certain types of law, such as a decree or executive order. Executive bureaucracies are commonly the source of regulations.
In the Westminster political system, the principle of separation of powers in not as entrenched. Members of the executive, called ministers, are also members of the legislature, and hence play an important part in both the writing and enforcing of law.
An executive officer (often abbreviated XO) is generally a person responsible for running an organization, although the exact nature of the role varies depending on the organization.
While there is no clear line between executive or principal and inferior officers, principal officers are high-level officials in the executive branch of U.S. government such as department heads of independent agencies. In Humphrey's Executor v. United States, 295 U.S. 602 (1935), the Court distinguished between executive officers and quasi-legislative or quasi-judicial officers by stating that the former serve at the pleasure of the president and may be removed at his discretion. The latter may be removed only with procedures consistent with statutory conditions enacted by Congress. The decision by the Court was that the Federal Trade Commission was a quasi-legislative body because of other powers it had, and therefore the president could not fire an FTC member for political reasons. Congress can’t retain removal power over officials with executive function (Bowsher v. Synar). However, statutes can restrict removal if not purely executive (Humphrey’s executor), but can't restrict removal of purely executive officer (Myers v. United States, 272 U.S. 52 (1926)). The standard is whether restriction "impedes the president’s ability to perform his constitutional duty" (Morrison v. Olson, 487 U.S. 654 (1988)).
Also Read ...MNF is a member of the BJP-led NEDA and is an ally of the NDA government headed by Prime MinisterNarendra Modi at the Centre. Moreover, as for the post of chief executive member (CEM), Laikaw said that the CEM post or executive body has to be formed within 48 hours of the removal of the existing government as per the rule ... Malvina ... ....
Sblendorio, ChiefExecutiveOfficer of Iveric Bio. “We are now focused on the execution of our full NDA submission and launch preparation, with the possibility of being first to market ... The company is on track to complete the final part of the NDA submission by the end of this year.
Inaugurating the facility, the Deputy ChiefExecutiveOfficer of NDA in-charge of Projects and Programmes, Stephen Yir-eru Engmen, said the facility formed part of the authority’s commitment to provide quality healthcare delivery to the door steps of the people in its operational areas.
We remain on track to file a New Drug Application (NDA) in 2023,” said Shalabh Gupta, M.D., ChiefExecutiveOfficer of Unicycive ... “We continue to execute our strategy and remain excited about the opportunities ahead for Unicycive as we advance our clinical studies and expand access to RENAZORB globally.
"This has been an important year for Sage, marked by the execution of significant milestones across our franchises. Looking ahead, we remain focused on the completion of the NDA submission for zuranolone in MDD and PPD, and are well into commercialization preparations to support a potential launch.
HCM, HKEX... Our team will continue to analyze the data and discuss these findings with the NMPA for possible NDA filing,” said Dr Weiguo Su, ChiefExecutiveOfficer and Chief Scientific Officer of HUTCHMED ... HUTCHMED is responsible for development and execution of all on-the-ground medical detailing, promotion and local and regional marketing ... The U.S ... .
We have progressed our lead nafamostat product candidate, Niyad™ to prepare for a potential Emergency Use Authorization in the first half of 2023 and initiated early commercial planning to ensure we're prepared for a potential launch next year," stated Vince Angotti, ChiefExecutiveOfficer of AcelRx.
- NDA submission based on ... "APHEXDA has the potential to significantly improve outcomes and treatment experiences for patients with multiple myeloma, and the acceptance of our NDA brings us closer to this important goal," said Philip Serlin, ChiefExecutiveOfficer of BioLineRx.
Mene Pangalos, ExecutiveVice President, BioPharmaceuticals R&D, AstraZeneca, said ... Under the terms of the agreement, Avillion became the trial sponsor responsible for executing and funding the multicenter, global clinical trial program for PT027 through NDA filing to a regulatory decision in the US.
“This has been an important year for Sage, marked by the execution of significant milestones across our franchises. Looking ahead, we remain focused on the completion of the NDA submission for zuranolone in MDD and PPD, and are well into commercialization preparations to support a potential launch.
Let me first say I take my integrity very seriously ... On Aug ... I did not sign an NDA and I do not believe an NDA should exist between government agencies. This incident highlights the very reason why my office needs its own executive counsel, so that I can receive a second opinion on matters and avoid legal misinformation in the future ... .